Starpharma announces appointment of chief financial officer - Mirage News
Starpharma (ASX:SPL) has announced the appointment of Justin Cahill as its chief financial officer and company secretary. Mr Cahill, who will commence
Mar 7, 2023
Starpharma
Hospitals & Physicians Clinics · Australia · 50 Employees
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy forthe management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.Read More
Who is Starpharma
Headquarters
4-6 Southampton Cres, Abbotsford, Victoria, 3067, Australia
Phone Number
(989) 774-2322
Website
Revenue
<$5M
Stock Symbol
SPL
Industry
Starpharma's Social Media
Popular Searches
Starpharma Holdings
Starpharma Holdings Ltd
Starpharma
Starpharma Ltd
Starpharma Pty Ltd
Top Competitors of Starpharma
Starpharma Org Chart
Starpharma Tech Stack
Starpharma News & Media
- Mar 7, 2023
Starpharma Holdings (ASX:SPL) shareholders have endured a 60% loss from investing in the stock five years ago
Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...Jan 2, 2023VIRALEZE Nasal Spray to be distributed in Hong Kong and Macau
MELBOURNE, Australia, Oct. 25, 2022 /PRNewswire/ -- An antiviral barrier nasal spray called VIRALEZE™ will launch in Hong Kong and Macau in the coming weeks, following a recent sales and distribution agreement between the product's developer Starpharma and Hengan Pharmacare Company Limited, a subsidiary of Hengan International Group Company Limited. Developed by Australian biotechnology company Starpharma, VIRALEZE™ is a broad-spectrum nasal spray intended to provide a moisturising and protectivOct 25, 2022Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer...Sep 12, 2022
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new DEP® program will generate and evaluate additional...Aug 10, 2022
Read more news
Frequently Asked Questions regarding Starpharma
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom... Read More
